Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific director
Scientific production - Institute for Cancer Research
| Publications | Doctoral theses | |
| 2013 | so far | |
| 2012 | 192 | 18 |
| 2011 | 183 | 22 |
| 2010 | 198 | 11 |
| 2009 | 167 | 21 |
| 2008 | 144 | 11 |
Print this page [103569 visits]Latest news
Publication in Nature Genetics on testicular cancer susceptibility
Rolf Skotheim (photo) is the site responsible in Oslo, and says that across all types of cancer, testicular cancer is now the type for which known susceptibility genes explain the largest fraction the genetic risk.
The story of PCI popularized and presented in national media
Kristian Berg at the Department of Radiation Biology at the Institute for Cancer Research played a key role in when the technique of "photochemical internalization" (PCI) was developed. This method was introduced in 1995.
The story behind PCI is widely presented in a popularized form on the web page of the Norwegian Broadcasting Corporation (NRK) as well as on the much visited Norwegian popular science web site "forskning.no".
Llorente and coworkers publish detailed lipidomic analyses of exosomes released from prostate cancer cells
Project group leader Alicia Llorente, working in the group of Kirsten Sandvig, has recently published the lipid composition of a prostate cancer cell line and of the exosomes released from these cells.
The work was performed in collaboration with two Finnish research groups and published in Biochim. Biophys. Acta (Mol. Cell Biol. Lip.; journal impact factor 5.3). The study, based on the quantification of 280 molecular lipid species, provides the most extensive lipid analysis of cells and their released exosomes to date.
Annetine Staff appointed "Scientist of the Month" by "Helse Sør-Øst" for April 2013
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".
For the month of April 2013, this honor goes to Annetine Staff from the Department of Gynaecology at the Women and Childrens Division at Oslo University Hospital.
Awards from Oslo University Hospital to outstanding research
On Friday April 26th nine research awards were distributed to scientists from Oslo University Hospital. The prizes were given out by Bjørn Erikstein, managing director at the hosptital during a ceremony taking place at Rikshospitalet, Gaustad.
Awards went to six excellent research articles. For the first time, prizes also were given to three individual researchers. The "Excellent Researcher Award" was won by Harald Stenmark. The two "Early Career Awards" went to Guro Elisabeth Lind and Tom Hemming Karlsen.
Work on selective tankyrase inhibitor from Krauss and collaborators highlighted as cover story in Sci-Bx
A research team from SFI-CAST Innovation center at the Oslo University Hospital, led by Stefan Krauss, and including Jo Waaler, Daniel Holsworth, Andrew Voronkov and Jens Preben Morth have developed a highly selective tankyrase inhibitor. Tankyrase is a druggable target in the otherwise hard-to-hit Wnt signaling pathway and has implications in colon cancer, pancreas adenocarcinoma, ovary cancer, lung cancer and other solid tumors. The tankyrase inhibitor may open a new therapeutic approach.
Latest publications
Inst. for Cancer Research
High-Purity Hydrogen via the Sorption-Enhanced Steam Methane Reforming Reaction over a Synthetic CaO-Based Sorbent and a Ni Catalyst
Environ Sci Technol (in press)
PubMed 23675760
Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer
PLoS One, 8 (5), e63723
PubMed 23675504
Sustained EKR inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy
Biochim Biophys Acta, 1830 (3), 2659-70
PubMed 23671927
Selected publications
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
High-Purity Hydrogen via the Sorption-Enhanced Steam Methane Reforming Reaction over a Synthetic CaO-Based Sorbent and a Ni Catalyst
Environ Sci Technol (in press)
PubMed 23675760
A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells
FASEB J (in press)
PubMed 23671272
Influence of KIR gene copy number on natural killer cell education
Blood (in press)
PubMed 23637128
